NeuroSense announces shareholder letter availability
Reuters2026/08/13 13:36- NeuroSense Therapeutics released a CEO letter to shareholders outlining near-term priorities for PrimeC in ALS.
- FDA clearance received to start the Phase 3 PARAGON study; planned enrollment about 300 participants, mainly in the US.
- Financing to run PARAGON has taken longer than expected; talks continue with strategic partners, investors, grants, non-dilutive sources.
- Canada regulatory path pursued; New Drug Submission for PrimeC targeted for December 2026, based on Phase 2b PARADIGM data.
- Nasdaq compliance efforts focus on bid-price; board authority sought for a 1-for-4 to 1-for-40 reverse split if needed.
- CEO Alon Ben-Noon, CFO Or Eisenberg invested USD 200,000 each in April 2026; combined with another investor totaled USD 600,000.
- https://www.neurosense-tx.com/
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
